Publications

The CNODES network of researchers, trainees, and analysts conduct studies using administrative healthcare data in response to queries from Canadian regulators. The results of these studies are published in open-access academic journals. CNODES also publishes a selection of its methodological advances, knowledge translation initiatives, and trainee projects.

Sultana J, Trotta F, Addis A, Brown JS, Gil M, Menniti-Ippolito F, Milozzi F, Suissa S, Trifirò G. Healthcare Database Networks for Drug Regulatory Policies: International Workshop on the Canadian, US and Spanish Experience and Future Steps for Italy. Drug Saf. 2020 Jan;43(1):1-5.

Suissa M, LeLorier J. The Pharmacologically Pertinent Period of Effect (PPPE). Pharmacoepidemiol Drug Saf. 2020 Jan;29 Suppl 1:61-67.

Platt RW, Platt R, Brown JS, Henry DA, Klungel OH, Suissa, S. How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias. Pharmacoepidemiol Drug Saf. 2020 Jan;29 Suppl 1:3-7.

Yu YH, Filion KB, Bodnar LM, Brooks MM, Platt RW, Himes KP, Naimi AI. Visualization tool of variable selection in bias-variance tradeoff for inverse probability weights. Ann Epidemiol. 2020 Jan;41:56-59.

Platt RW, Henry D, Suissa S. The Canadian Network for Observational Drug Effect Studies (CNODES): Reflections on the First Eight Years, and a Look to the Future. Pharmacoepidemiol Drug Saf. 2020 Jan;29 Suppl 1:103-107.

Secrest MH, Platt RW, Reynier P, Dormuth CR, Benedetti A, Filion KB. Multiple imputation for systematically missing confounders within a distributed data drug safety network: A simulation study and real-world example. Pharmacoepidemiol Drug Saf. 2020 Jan;29 Suppl 1:35-44.

Wu JW, Azoulay L, Huang A, Paterson M, Wu F, Secrest MH, Filion KB. Identification of incident pancreatic cancer in Ontario administrative health data: A validation study. Pharmacoepidemiol Drug Saf. 2020 Jan;29 Suppl 1:78-85.

Secrest MH, Platt RW, Dormuth CR, Chateau D, Targownik L, Nie R, Doyle CM, Dell’Aniello S, Filion KB. Extreme restriction design as a method for reducing confounding by indication in pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf. 2020 Jan;29 Suppl 1:26-34.

Secrest MH, Azoulay L, Dahl M, Clemens KK, Durand M, Hu N, Targownik L, Turin TC, Dormuth CR, Filion KB. A population-based analysis of anti-diabetic medications in four Canadian provinces: secular trends and prescribing patterns. Pharmacoepidemiol Drug Saf. 2020 Jan;29 Suppl 1:86-92.

Doyle CM, Lix LM, Hemmelgarn BR, Paterson JM, Renoux C. Data variability across Canadian administrative health databases: differences in content, coding, and completeness. Pharmacoepidemiol Drug Saf. 2020 Jan;29 Suppl 1:68-77.